Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

NCT04215978 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04215978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04215978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2020
Completion date
January 24, 2025
Enrollment
204 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, head and neck squamous cell carcinoma (hnscc), nasopharyngeal carcinoma (npc), non small cell lung cancer